The Effect of Canertinib on Sensitivity of Cytotoxic Drugs in Tamoxifen-Resistant Breast Cancer Cells In Vitro

about

The Effect of Canertinib on Sensitivity of Cytotoxic Drugs in Tamoxifen-Resistant Breast Cancer Cells In Vitro

Item

http://www.wikidata.org/entity/Q58697915

description

scientific article published on 23 October 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

The Effect of Canertinib on Se ...... t Breast Cancer Cells In Vitro

@en

The Effect of Canertinib on Se ...... t Breast Cancer Cells In Vitro

@nl

type

Item

label

The Effect of Canertinib on Se ...... t Breast Cancer Cells In Vitro

@en

The Effect of Canertinib on Se ...... t Breast Cancer Cells In Vitro

@nl

prefLabel

The Effect of Canertinib on Se ...... t Breast Cancer Cells In Vitro

@en

The Effect of Canertinib on Se ...... t Breast Cancer Cells In Vitro

@nl

P1476

The Effect of Canertinib on Se ...... t Breast Cancer Cells In Vitro

@en

P2093

Hesham A M Gomaa

http://www.w3.org/2001/XMLSchema#string

M A Kandeil

http://www.w3.org/2001/XMLSchema#string

P2860

The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC-gamma

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

A small molecule-kinase interaction map for clinical kinase inhibitors

Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor.

CI-1033, a pan-erbB tyrosine kinase inhibitor.

Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia.

Promising new molecular targeted therapies in head and neck cancer.

ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.

Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).

P304

7628734

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/7628734

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Mohamed Abdel-Gabbar

Asmaa T Ali

P577

2018-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30425998

http://www.w3.org/2001/XMLSchema#string

P921

molecular biology

P932

6218737

http://www.w3.org/2001/XMLSchema#string